EP3096756
CRF1 viðtaka-mótlyf til meðhöndlunar á meðfæddum ofvexti nýrnahettu
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.1.2015EP published:
12.6.2024EP application number:
15702917.4
EP translation filed:
12.8.2024Grant published:
15.9.2024EPO information:
European Patent Register
Max expiry date:
20.1.2035Expiry date:
20.1.2027Next due date:
31.1.2027
Title in English:
CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIALanguage of the patent:
English
Timeline
Today
21.1.2015EP application
12.6.2024EP Publication
12.8.2024Translation submitted
15.9.2024Registration published
20.1.2027Expires
Owner
Name:
NEUROCRINE BIOSCIENCES, INC.Address:
12790 El Camino Real, San Diego, CA 92130-1102, US
Inventor
Name:
GRIGORIADIS, Dimitri, E.Address:
San Diego, California 92130, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201461929941 PDate:
21.1.2014Country:
US
Number:
201461981033 PDate:
17.4.2014Country:
US
Number:
201462069155 PDate:
27.10.2014Country:
US
Classification
Categories:
A61K 31/427, A61K 31/519, A61K 31/4985, A61P 5/38
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 8.1.2025
Expires: 20.1.2026
Payer: Árnason Faktor ehf.
Number: 12
Paid: 13.1.2026
Expires: 20.1.2027
Payer: Árnason Faktor ehf.